This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, P. C. Articles by Timmermans, P. B. Search for Related Content PubMed PubMed Citation Articles by Wong, P. C. Articles by Timmermans, P. B.

Hypertension, Vol 15, 823-834, Copyright © 1990 by American Heart Association

ARTICLES

Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753

PC Wong, WA Price Jr, AT Chiu, DJ Carini, JV Duncia, AL Johnson, RR Wexler and PB Timmermans
Medical Products Department, E. I. du Pont de Nemours & Company, Wilmington, Delaware 19880-0400.

A series of nonpeptide angiotensin II (Ang II) receptor antagonists was evaluated in rat adrenal cortical microsomes for their inhibitory effects on the specific binding of [3H]Ang II, in the isolated rabbit aorta bioassay for their functional antagonism of contractile response to Ang II, and in high renin, renal-hypertensive rats for their intravenous antihypertensive effects, expressed as IC50, pA2, and intravenous ED30, respectively. Highly significant linear correlations were found between IC50 and pA2 (r = -0.88), between IC50 and intravenous ED30 (r = 0.79), and between pA2 and intravenous ED30 (r = - 0.93). In both in vitro and in vivo functional assays, none of these antagonists exhibited agonistic effects. The orally active nonpeptide Ang II receptor antagonists EXP9270 and DuP 753 (oral ED30 = 3.6 and 0.59 mg/kg, respectively) were selected for further characterization. These antagonists exhibited selective and competitive Ang II antagonism in rabbit aorta and guinea pig ileum. In conscious normotensive rats, DuP 753 abolished the pressor response to saralasin, suggesting that the pressor effect of saralasin is attributed to its Ang II-like activity. In addition, DuP 753 also blocked the Ang II-induced drinking response and aldosterone release in rats. These results suggest that Ang II receptor blockade is the primary mechanism of the antihypertensive effect of these nonpeptide Ang II receptor antagonists. Further, the specificity and lack of partial agonistic effects of these molecules make them potentially useful physiological probes and therapeutic agents.

This article has been cited by other articles:

				D. M. Roesch, Y. Tian, W. Zheng, M. Shi, J. G. Verbalis, and K. Sandberg Estradiol Attenuates Angiotensin-Induced Aldosterone Secretion in Ovariectomized Rats Endocrinology, December 1, 2000; 141(12): 4629 - 4636. [Abstract] [Full Text] [PDF]

				S. MYOU, M. FUJIMURA, Y. KAMIO, Y. ISHIURA, K. KURASHIMA, H. TACHIBANA, T. HIROSE, and T. HASHIMOTO Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, on Bronchial Hyperresponsiveness to Methacholine in Patients with Bronchial Asthma Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 40 - 44. [Abstract] [Full Text]

				A. Nunez, J. Gomez, L. R. Zalba, M. Monton, A. Jimenez, S. Velasco, A. Lopez-Blaya, A. Celdran Uriarte, S. Casado, and A. Lopez-Farre Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 175 - 179. [Abstract] [PDF]

				T.-C. Fang and W.-C. Huang Angiotensin Receptor Blockade Blunts Hyperinsulinemia-Induced Hypertension in Rats Hypertension, August 1, 1998; 32(2): 235 - 242. [Abstract] [Full Text] [PDF]

				J. T. FITZSIMONS Angiotensin, Thirst, and Sodium Appetite Physiol Rev, July 1, 1998; 78(3): 583 - 686. [Abstract] [Full Text] [PDF]

				D. H. Wang, J. Qiu, Z. Hu, and Y. Du Regulation of Type 1 Angiotensin II Receptor in Adrenal Gland : Role of {alpha}1-Adrenoreceptor Hypertension, September 1, 1997; 30(3): 345 - 350. [Abstract] [Full Text]

				S. K. Gandhi, D. H. Ryder, and N. J. Brown Losartan Blocks Aldosterone and Renal Vascular Responses to Angiotensin II in Humans Hypertension, December 1, 1996; 28(6): 961 - 966. [Abstract] [Full Text]

				F. H. Messerli, M. A. Weber, and H. R. Brunner Angiotensin II Receptor Inhibition: A New Therapeutic Principle Arch Intern Med, September 23, 1996; 156(17): 1957 - 1965. [Abstract] [PDF]

				M. T. Velasquez Angiotensin II Receptor Blockers: A New Class of Antihypertensive Drugs Arch Fam Med, June 1, 1996; 5(6): 351 - 356. [Abstract] [PDF]

				J. H. Bauer and G. P. Reams The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs Arch Intern Med, July 10, 1995; 155(13): 1361 - 1368. [Abstract] [PDF]

				I. M. Bird, R. A. Word, C. Clyne, J. I. Mason, and W. E. Rainey Potassium Negatively Regulates Angiotensin II Type 1 Receptor Expression in Human Adrenocortical H295R Cells Hypertension, June 1, 1995; 25(6): 1129 - 1134. [Abstract] [Full Text]

				W. C. De Mello Influence of Intracellular Renin on Heart Cell Communication Hypertension, June 1, 1995; 25(6): 1172 - 1177. [Abstract] [Full Text]

				E. Delacretaz, J. Nussberger, J. Biollaz, B. Waeber, and H. R. Brunner Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy Volunteers Hypertension, January 1, 1995; 25(1): 14 - 21. [Abstract] [Full Text]

				A. H. van den Meiracker, P. J.J. Admiraal, J. A. Janssen, J.-M. Kroodsma, W. A.M. de Ronde, F. Boomsma, J. Sissmann, P.J. Blankestijn, P. G.M. Mulder, A. J. Man in `t Veld, et al. Hemodynamic and Biochemical Effects of the AT1 Receptor Antagonist Irbesartan in Hypertension Hypertension, January 1, 1995; 25(1): 22 - 29. [Abstract] [Full Text]